Healthcare ❯Clinical Trials

Drug Efficacy

Transfusion Independence Zepbound Memory Improvement Weight Loss Drugs Patient Outcomes Obesity Treatment Zepbound Studies

Alnylam's Vutrisiran Shows Mixed Results in Cardiomyopathy Study

The heart disease drug met primary goals but fell short of investor expectations, leading to a significant stock drop.

Viking Therapeutics Advances Weight-Loss Drug, Shaking Up Market Leaders

Weight-Loss Drug Tirzepatide Shows Promise for Treating Sleep Apnea

Geron Shares Soar After FDA Approves New Blood Disorder Drug